HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Direct Drive Tech (PHIP Updates) - The Valuation Is Already Expensive

Pre-IPO Junlebao Dairy Group - The Strength and the Concerns

Pre-IPO SKG Health Technologies - The Industry, the Business and the Concerns

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

Equity Capital Markets

<ul>
<li>Megatronix’s revenue structure shows it has not yet shaken off its "hardware supplier" positioning and is far from the technical vision of "software-defined mobility". Automakers’ self-R&amp;D efforts have brought challenges.</li>
<li>Megatronix has not been able to establish a developer ecosystem.Its pure software solution is being rapidly eroded by the technological moat under the pressure from the giants in the ecosystem.</li>
<li>Based on the analysis, the conservative scenario could be P/S of 3-4x. the neutral scenario could be P/S of 4-5x, and the optimistic scenario could be P/S of 5-6x. </li>
</ul>


Megatronix’s revenue structure shows it has not yet shaken off its "hardware supplier" positioning and is far from the technical vision of "software-defined mobility". Automakers’ self-R&amp;D efforts have brought challenges.
Megatronix has not been able to establish a developer ecosystem.Its pure software solution is being rapidly eroded by the technological moat under the pressure from the giants in the ecosystem.
Based on the analysis, the conservative scenario could be P/S of 3-4x. the neutral scenario could be P/S of 4-5x, and the optimistic scenario could be P/S of 5-6x. 


Pre-IPO Megatronix Inc. - Far from Achieving the Ecosystem Synergy